Researchers indicated that a lack of understanding of the mechanism and efficacy of PD-1/PD-L1 inhibitors is the major barrier for prescription of these inhibitors in Chinese tumor treatment-related departments.
Liver, Gallbladder, and Biliary Tract Cancers
The company’s application is based on results from the phase III IMbrave150 study of the regimen for the treatment of patients with unresectable hepatocellular carcinoma who have not received prior systemic therapy.
High-quality patient reported outcomes were observed, suggesting benefits in key aspects of the patient experience with this combination treatment.
The FDA has granted a priority review to a new drug application for pemigatinib as a treatment for patients with previously treated, locally advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements.
Predictive models demonstrated the ability to anticipate adverse opioid-related outcomes among cancer survivors.
The FDA has accepted the supplemental biologics license application and granted breakthrough therapy designation to nivolumab plus ipilimumab for the treatment of patients with advanced hepatocellular carcinoma previously treated with sorafenib.
A new combination may help with overall and progression-free survival in liver cancer.
Intraoperative bile spillage might serve as a prognostic tool for gall bladder cancer.
Researchers recently reported on the association between upregulation of EPS8L3 and liver cancer prognosis.
Therapy options for patients with hepatocellular carcinoma (HCC), including a newly approved therapy for a subpopulation of patient.